衞寧健康(300253.SZ)2021年度淨利潤預降5%-30%
格隆匯1月24日丨衞寧健康(300253.SZ)公佈，預計2021年度歸屬於上市公司股東的淨利潤3.44億元-4.67億元，同比下降5%-30%；扣除非經常性損益後的淨利潤1.87億元-2.98億元，同比下降20%-50%。業績變動原因如下：
1、報吿期內，公司持續深化“雙輪驅動”發展戰略，繼續堅持以市場為導向，憑藉專業、成熟、全面的產品和服務持續開展主營業務，持續進行技術創新、產品創新和模式創新，繼續加強在國內同行業中的領先地位。
但由於受新冠肺炎疫情的間發性影響，全國多地一段時間內(尤其是第四季度受新冠變異株奧密克戎的影響)實施了較為嚴格的疫情防控措施，部分地區公共交通和人員流動受阻，致使醫療衞生信息化行業上下游的部分項目招投標、項目實施、項目回款等有所延後，導致業務開展受到一定影響。根據截至目前初步統計，傳統的醫療衞生信息化業務新簽訂單合同金額同比增長25%以上，預計全年公司總的營業收入同比增長約20%-25%，其中核心產品軟件銷售及技術服務收入同比增長約10%-15%，硬件銷售收入同比小幅下降。
2、公司互聯網醫療健康業務整體呈現加速發展態勢，其中納入合併報表範圍內的互聯網醫療健康業務收入預計超過5億元，同比增長超過200%。代表企業衞寧互聯網科技有限公司(衞寧互聯網)及其控股子公司納裏健康科技有限公司(納裏健康)、衞寧沄鑰科技(上海)有限公司(沄鑰科技)、上海金仕達衞寧軟件科技有限公司(衞寧科技)合計收入預計超過6億元，同比快速增長，增速較上年增速明顯加快，但因報吿期內戰略性投入加大等原因，虧損額同比增加較多，預計對合並報表歸母淨利潤影響約-8000萬元左右。
3、本年度因實施股權激勵計劃以及發行可轉換公司債券，確認以權益結算的股份支付費用以及可轉債利息計提合計約1.35億元(上年同期約8000萬元)，較上年增加約5500萬元，對淨利潤有所影響。
4、受應收賬款餘額加大及回款影響，計提壞賬準備同比增長約70%-100%，對淨利潤影響較大。
5、報吿期內，預計非經常性損益對淨利潤的影響金額約1.62億元(上年同期約1.18億元)，主要為其他金融資產的公允價值變動、政府補助等影響。
6、基於主要子公司的經營情況及其未來發展前景，經公司管理層初步估算，預計2021年度無需計提商譽減值準備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
